Research programme: DNA-based cancer immunotherapies - OncoSec Medical

Drug Profile

Research programme: DNA-based cancer immunotherapies - OncoSec Medical

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoSec Medical
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference; Interleukin 12 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Nov 2017 Preclinical trials in Cancer in USA (Parenteral) before November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top